Holen Sie sich die Stockscreener-App
17.33
10.91%
-1.8204
Schlusskurs vom Vortag:
$19.15
Offen:
$19.3
24-Stunden-Volumen:
87,772
Relative Volume:
0.06
Marktkapitalisierung:
$170.88M
Einnahmen:
$88.50M
Nettoeinkommen (Verlust:
$-35.27M
KGV:
-5.2587
EPS:
-3.2954
Netto-Cashflow:
$-23.70M
1W Leistung:
-9.16%
1M Leistung:
+49.00%
6M Leistung:
+127.41%
1J Leistung:
+14.76%
1-Tages-Spanne:
$17.03
$20.20
1-Wochen-Bereich:
$17.03
$20.21
52-Wochen-Spanne:
$3.436
$20.21
Biodesix Inc Stock (BDSX) Company Profile
Firmenname
Biodesix Inc
Sektor
Branche
Telefon
303-417-0500
Adresse
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
17.33 | 188.79M | 88.50M | -35.27M | -23.70M | -3.2954 |
|
TMO
Thermo Fisher Scientific Inc
|
466.07 | 176.79B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
186.93 | 131.71B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
572.53 | 45.48B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.42 | 31.55B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
285.92 | 27.79B | 3.17B | 642.63M | 516.49M | 10.77 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-26 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-13 | Eingeleitet | TD Cowen | Buy |
| 2024-05-03 | Eingeleitet | Lake Street | Buy |
| 2021-11-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | Eingeleitet | BTIG Research | Buy |
| 2020-11-23 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-23 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Biodesix Inc Aktie (BDSX) Neueste Nachrichten
Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference - MarketBeat
Recap Report: What is the dividend yield of Biodesix IncNew Guidance & Accurate Trade Setup Notifications - baoquankhu1.vn
Biodesix at Barclays Conference: Strategic Growth in Lung Cancer Diagnostics - Investing.com Canada
Biodesix Earnings Call Signals Growth With Caveats - TipRanks
Setup Watch: Is Biodesix Inc in a consolidation phase2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference - MarketBeat
What analysts say about Biodesix Inc stock2025 Dividend Review & Daily Stock Momentum Reports - baoquankhu1.vn
How The Biodesix (BDSX) Investment Story Is Shifting After Guidance And New US$30 Target - Yahoo Finance
Wall Street experts predict that Biodesix (BDSX) may climb by 111.62%: Consider this information before making an investment decision - Bitget
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet - Finviz
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
BDSX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monashee Investment Management Cuts Biodesix Stake by 95% - National Today
Are healthcare stocks underperforming Biodesix (BDSX) so far this year? - Bitget
Canaccord reiterates Biodesix stock rating on strong Q4 results By Investing.com - Investing.com Canada
Canaccord reiterates Biodesix stock rating on strong Q4 results - Investing.com
Biodesix (BDSX) Q4 2025 Earnings Call Transcript - AOL.com
Monashee Investment Management LLC Cuts Holdings in Biodesix, Inc. $BDSX - MarketBeat
Q4 2025 Biodesix Inc Earnings Call Transcript - GuruFocus
William Blair Upgrades Biodesix (BDSX) - Nasdaq
William Blair Upgrades BDSX (Biodesix, Inc.) to Outperform Feb 2026 - Meyka
Biodesix (NASDAQ:BDSX) Announces Quarterly Earnings Results, Beats Estimates By $0.56 EPS - MarketBeat
William Blair Upgrades Biodesix (BDSX) to 'Outperform' | BDSX St - GuruFocus
Biodesix expects 2026 sales to crack $100M - BizWest
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
William Blair Upgrades Biodesix to Outperform From Market Perform - marketscreener.com
GSA Capital Partners LLP Has $365,000 Stake in Biodesix, Inc. $BDSX - MarketBeat
William Blair upgrades Biodesix stock rating on execution momentum By Investing.com - Investing.com Australia
Earnings call transcript: Biodesix Q4 2025 shows strong revenue growth and positive EBITDA By Investing.com - Investing.com South Africa
William Blair upgrades Biodesix stock rating on execution momentum - Investing.com Nigeria
Biodesix Inc (BDSX) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Biodesix, Inc. Q4 Loss Drops - Nasdaq
Biodesix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Biodesix Q4 2025 shows strong revenue growth and positive EBITDA - Investing.com India
BDSX Projects 80% Gross Margin and Revenue Growth for FY26 - GuruFocus
Biodesix Inc (NASDAQ:BDSX) Reports Q4 2025 Earnings Beat and First Adjusted EBITDA Profitability - ChartMill
Biodesix Q4 Earnings Call Highlights - MarketBeat
Biodesix (BDSX) Surpasses Revenue Expectations in Q4 with 41% Gr - GuruFocus
Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Biodesix Inc. (BDSX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Biodesix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights - TradingView
Biodesix (NASDAQ: BDSX) hits first positive EBITDA on 41% Q4 growth - Stock Titan
BRIEF-Biodesix Q4 Adjusted Operating Expenses USD 25.8 Million - TradingView
Biodesix, Inc. (BDSX) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Earnings To Watch: Biodesix Inc (BDSX) Reports Q4 2025 Result - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences - Caledonian Record
Finanzdaten der Biodesix Inc-Aktie (BDSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):